These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22833579)

  • 21. Reasons for increased substance use in psychosis.
    Gregg L; Barrowclough C; Haddock G
    Clin Psychol Rev; 2007 May; 27(4):494-510. PubMed ID: 17240501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Addiction and schizophrenia. Nosological, clinical and therapeutic questions. 2. Substance dependence and schizophrenia].
    Soyka M
    Fortschr Neurol Psychiatr; 1994 Jun; 62(6):186-96. PubMed ID: 8050773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neural basis of psychosis-related behaviour in the infection model of schizophrenia.
    Meyer U; Feldon J
    Behav Brain Res; 2009 Dec; 204(2):322-34. PubMed ID: 19154759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The coherence of the evidence linking cannabis with psychosis.
    Henquet C; Van Os J
    Psychol Med; 2008 Mar; 38(3):461-2; author reply 462-4. PubMed ID: 18298878
    [No Abstract]   [Full Text] [Related]  

  • 25. Genetic dissection of the psychotomimetic effects of cannabinoid exposure.
    O'Tuathaigh CM; Gantois I; Waddington JL
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jul; 52():33-40. PubMed ID: 24239593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Inhalant abusers and psychiatric symptoms].
    Okudaira K; Yabana T; Takahashi H; Iizuka H; Nakajima K; Saito A
    Seishin Shinkeigaku Zasshi; 1996; 98(4):203-12. PubMed ID: 8710994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample.
    Kendler KS; Ohlsson H; Sundquist J; Sundquist K
    Am J Psychiatry; 2019 Sep; 176(9):711-719. PubMed ID: 31055966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis.
    Dragt S; Nieman DH; Schultze-Lutter F; van der Meer F; Becker H; de Haan L; Dingemans PM; Birchwood M; Patterson P; Salokangas RK; Heinimaa M; Heinz A; Juckel G; Graf von Reventlow H; French P; Stevens H; Ruhrmann S; Klosterkötter J; Linszen DH;
    Acta Psychiatr Scand; 2012 Jan; 125(1):45-53. PubMed ID: 21883099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic variants of D2 but not D3 or D4 dopamine receptor gene are associated with rapid onset and poor prognosis of methamphetamine psychosis.
    Ujike H; Katsu T; Okahisa Y; Takaki M; Kodama M; Inada T; Uchimura N; Yamada M; Iwata N; Sora I; Iyo M; Ozaki N; Kuroda S
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Jun; 33(4):625-9. PubMed ID: 19275926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems.
    Fantegrossi WE; Wilson CD; Berquist MD
    Drug Metab Rev; 2018 Feb; 50(1):65-73. PubMed ID: 29385930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contrasting models of genetic co-morbidity for cannabis and other illicit drugs in adult Australian twins.
    Agrawal A; Lynskey MT; Bucholz KK; Martin NG; Madden PA; Heath AC
    Psychol Med; 2007 Jan; 37(1):49-60. PubMed ID: 17076916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Molecular mechanism for methamphetamine-induced memory impairment].
    Nagai T; Yamada K
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2010 Apr; 45(2):81-91. PubMed ID: 20486560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An association study of monoamine oxidase A (MAOA) gene polymorphism in methamphetamine psychosis.
    Nakamura K; Sekine Y; Takei N; Iwata Y; Suzuki K; Anitha A; Inada T; Harano M; Komiyama T; Yamada M; Iwata N; Iyo M; Sora I; Ozaki N; Ujike H; Mori N
    Neurosci Lett; 2009 May; 455(2):120-3. PubMed ID: 19368859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substance-induced psychotic disorders: 13-year data from a de-addiction centre and their clinical implications.
    Aggarwal M; Banerjee A; Singh SM; Mattoo SK; Basu D
    Asian J Psychiatr; 2012 Sep; 5(3):220-4. PubMed ID: 22981049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis.
    Kishimoto M; Ujike H; Motohashi Y; Tanaka Y; Okahisa Y; Kotaka T; Harano M; Inada T; Yamada M; Komiyama T; Hori T; Sekine Y; Iwata N; Sora I; Iyo M; Ozaki N; Kuroda S
    Biol Psychiatry; 2008 Jan; 63(2):191-6. PubMed ID: 17555717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis.
    Sato M
    Ann N Y Acad Sci; 1992 Jun; 654():160-70. PubMed ID: 1632581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis.
    Ujike H; Sato M
    Ann N Y Acad Sci; 2004 Oct; 1025():279-87. PubMed ID: 15542728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mayo Seminars in Psychiatry: dopamine and schizophrenia--a review.
    Fredrickson P; Richelson E
    J Clin Psychiatry; 1979 Sep; 40(9):399-405. PubMed ID: 39063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cannabis and cannabinoid receptors--abuse and psychosis].
    Hjorthøj C; Nordentoft M; Fink-Jensen A
    Ugeskr Laeger; 2008 Nov; 170(46):3782-4. PubMed ID: 19014732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Do alcohol or drug abuse induce schizophrenia?].
    Hambrecht M; Häfner H
    Nervenarzt; 1996 Jan; 67(1):36-45. PubMed ID: 8676987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.